Accellent new name for post-MedSource UTI:
This article was originally published in Clinica
UTI, a contract manufacturing, design and engineering company serving the medical device sector, has been renamed Accellent. The change comes after the firm acquired Minneapolis, Minnesota-based MedSource for $230m in June. The new group will be headquartered in Boston, Massachusetts, and will retain a key manufacturing centre at Collegeville, Pennsylvania. The company has three divisions: orthopaedics and endoscopy (both based in the Boston area); and cardiology, in Minneapolis.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.